M

1

6. (Amended) A method according to [any one of] claim[s] 1 [to 5] wherein the viral infection is a hepatitis infection or other viral infection of the human or animal liver.

- 7. (Amended) A method according to [any one of] claim[s] 2 [to 6] wherein said cell is a liver cell.
- 8. (Amended) A substance identified by the method of [any one of the preceeding claims]claim 1.
- 13. (Amended) [A] An isolated polynucleotide encoding a protein according to claim 11 [or 12 sequence for use in affecting a viral infection].
- 14. (Amended) A pharmaceutical composition for treating viral infections in a mammal, comprising [Use of] a protein according to claim 11 [or 12, or a polynucleotide according to claim 13 in the manufacture of a medicament for use in affecting a viral infection], and a pharmaceutically acceptable non-toxic vehicle.
- 15. (Amended) A pharmaceutical composition for treating viral infections in a mammal, comprising [Use of a substance in the manufacture of a medicament for use in affecting a viral infection, wherein the a substance [has been] identified by the method of [any one of] claim[s] 1 [to 7], and a pharmaceutically acceptable non-toxic vehicle.
- 16. (Amended) A pharmaceutical composition for treating viral infections in a mammal, comprising [Use of a substance in the manufacture of a medicament for the use in affecting a viral infection wherein said] a substance which can upregulate expression of ADRP in a mammalian cell, and a pharmaceutically acceptable non-toxic vehicle.

Please delete Claim 9,

Please add the following claims:

- or other viral infection of the human or animal liver.
 - 18. A method according to claim-5 wherein said cell is a liver cell.
 - 19 A substance identified by the method of claim 5.
 - 20. A pharmaceutical composition for treating viral infections in a mammal, comprising a polynucleotide according to claim 13 in the manufacture of a medicament for use in affecting a viral infection, and a pharmaceutically acceptable non-toxic vehicle.